Can My Doctor Prescribe Compounded Tirzepatide?

Yes. Any doctor with a license in your state can prescribe tirzepatide. So can a nurse practitioner or physician assistant, within the limits your state sets.^{1, 2, 3, 4} For the FDA-approved brands, Zepbound for weight and sleep apnea and Mounjaro for type 2 diabetes, it is an ordinary prescription.^{5, 6}

Your doctor can also prescribe compounded tirzepatide, which a pharmacy prepares itself rather than dispensing Zepbound or Mounjaro. FDA's advice is to prescribe an FDA-approved drug when one is available and appropriate for you, and to keep compounded drugs for people whose medical needs an approved drug can't meet.^{7, 8} Compounded tirzepatide has no FDA approval, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.⁷

The rules are tighter, too. A state-licensed pharmacy may supply compounded tirzepatide only to a named patient, on a valid prescription.^{9, 10} Since the shortage ended, that pharmacy may not routinely make what FDA calls copies of Zepbound or Mounjaro unless your prescriber documents a specific change that creates a significant difference for you.^{9, 11} A lower price does not count, and FDA's examples include leaving out a dye the patient is allergic to.¹² Our provider guide explains the full compounding rules. Some doctors decline: in one health system's survey, 57% of clinicians and pharmacists had not used compounded GLP-1s in practice.¹³

Two claims you may see elsewhere do not fit FDA's rules as restated on April 1, 2026: that doctors can prescribe compounded tirzepatide only during a shortage, and that pharmacies can no longer make it.¹¹

Covered below: who can prescribe, the written reason, why some doctors decline, approved routes, if your doctor agrees, screening and warning signs, getting it elsewhere, PlexusDx.

Who can write a tirzepatide prescription

Tirzepatide is a prescription-only medicine.⁵ Federal law lets a pharmacy fill a prescription drug only on a prescription from a practitioner licensed by law to administer it.¹ For compounded drugs, the compounding law asks for a licensed physician or another practitioner whom state law allows to prescribe.⁹

Neither rule names a specialty. A family doctor, internist, OB-GYN, endocrinologist or obesity specialist with that license can write it; whether they will is a clinical judgment.

• Nurse practitioners. State law sets their prescribing authority. The American Association of Nurse Practitioners describes full-practice states, where NPs prescribe under the board of nursing's authority alone, and reduced- or restricted-practice states, which require a career-long collaborative agreement with, or supervision by, another provider.³
• Physician assistants. PAs can generally prescribe. Their exact duties depend on their setting, experience, specialty and state law, and most states require them to have an agreement with a specific physician.⁴
• Telehealth clinicians. A clinician who treats you online needs a license, or other legal permission, to practice in the state you are in.²

Compounded tirzepatide needs that prescription for you as well. FDA warns against buying tirzepatide products falsely labeled "for research purposes," which it describes as of unknown quality and possibly harmful.⁷ Our provider guide lists those and other offers to walk away from.

What your prescriber has to write down now that the shortage is over

FDA found the tirzepatide injection shortage resolved on December 19, 2024.¹¹ Its test for a copy, restated in April 2026, compares the active ingredient, the strength and the route of administration. FDA intends to treat a compounded tirzepatide injection at or near a Zepbound or Mounjaro strength as one.¹¹ The exception is when your prescriber "determines and documents" a change that makes a significant difference for you.¹¹

Our provider guide explains the full rules for 503A pharmacies and 503B outsourcing facilities. What follows is the part that falls to your prescriber.

What the prescription has to show

Under FDA's guidance, a pharmacy that relies on the prescriber's decision should make sure it is documented on the prescription. Any format will do, as long as the prescription makes clear what the change is and the significant difference it will make for you. Your name and the formula alone are not enough.¹²

FDA's guidance gives three examples of a note that would be sufficient, none of them about tirzepatide:

• "No Dye X, patient allergy," when the approved product contains that dye;¹²
• "Liquid form, patient can't swallow tablet," when the approved product is a tablet;¹²
• "6 mg, patient needs higher dose," when the approved product is only available in a 5 mg dose.¹²

They show what a genuine medical reason looks like; they are not a script. Intentionally falsifying a prescription for a compounded drug is a prohibited act under federal law.¹⁰

An added ingredient is not a reason by itself: FDA may still consider semaglutide combined with vitamin B12 a copy when it is given the same way and both ingredients are within 10% of approved strengths.¹¹ Our provider guide covers added ingredients such as B12 and glycine.

Who checks the reason

• Your prescriber makes the call. For now, FDA generally does not intend to question a decision that is documented, but it does intend to check that one was documented.¹²
• The pharmacist looks for it. If the prescription is unclear, the pharmacy can call the prescriber and, if the prescriber confirms, note the change, the difference it makes and the date of the call on the prescription.¹²
• Your state's pharmacy board may put it more firmly. Ohio's board, in GLP-1 guidance issued July 17, 2025, says the pharmacy must make sure the reason is on the prescription and must contact the prescriber when it is missing.¹⁴

Supplies kept at a clinic

FDA's guidance says a 503A pharmacy can send out compounded drugs only against a valid prescription for a named patient.¹⁰ It points clinics that want supplies without patient names to outsourcing facilities, compounders registered with FDA under section 503B.¹⁰ Our provider guide's compounding law section covers what those facilities may make. If a clinic gives you compounded tirzepatide from its own stock, ask which pharmacy made it and whether it was made for you by name.

Why some doctors say no

A doctor who declines is not unusual. One survey, run from December 5, 2025 to January 4, 2026, asked clinicians and pharmacists across a multi-site U.S. health system about compounded GLP-1 and GIP/GLP-1 products. Of the 91 who answered, 52 (57%) had not used them in their practice. Their most common reasons were concerns about safety (63.5%), effectiveness (57.7%) and legality (51.9%), and a lack of confidence or knowledge about how to prescribe them (46.2%).¹³

Most respondents were not confident about how to prescribe a compounded product (82%) or how to send it to a licensed compounding pharmacy (77.3%). Read the figures with the study's limits: the survey went to 523 people and about 24% responded, 81% of the clinicians who answered practiced family medicine, and every response came from a single institution.¹³

Medical groups and malpractice insurers have also put their positions in writing:

Except for the 2025 American College of Clinical Pharmacy opinion, every dated row was issued before FDA's December 19, 2024 decision that the tirzepatide shortage was resolved, and MedPro's article is undated. MICA wrote about compounded semaglutide.^{11, 18}

The OMA FAQ also names reasons that should never be the only basis for prescribing a compounded peptide, among them avoiding the brand's prior authorization, convenience of administration, and cutting costs with a lower-quality pharmacy. Its checklist asks whether clinician and patient looked at other ways to get these medicines, such as drugmaker programs and insurance.¹⁹ The next section covers those routes for tirzepatide.

If you are the clinician. MedPro's advice includes checking your state medical and pharmacy boards' rules on prescribing GLP-1s and telling your liability insurer that you plan to prescribe them.²² For a product not on FDA's shortage list, OMA's checklist adds a question for your malpractice carrier about whether claims would be covered. It also asks whether you have the certificate of analysis, the test report federal law requires with each bulk drug substance a compounder uses.^{9, 19}

Approved tirzepatide to ask about first

If cost or coverage is why you asked, an FDA-approved route may solve the same problem. Each one still depends on the screening below.

• Your plan covers Zepbound. If it needs prior authorization (approval before it pays) or says no, our prior authorization guide covers the request and appeals; check the denial letter for your deadline to appeal. If your commercial plan covers Zepbound and the prescription is for an approved use, a Lilly savings card may lower what you pay.²³ See which drugmaker offers fit your coverage.
• You would pay cash. Your doctor can send the prescription to LillyDirect, the only place that sells Zepbound single-dose vials.²⁴ Our tirzepatide cost page prices each dose and a full year of fills.
• You have Medicare Part D. Medicare's temporary GLP-1 Bridge, running since July 1, 2026, pays for the Zepbound KwikPen (one pen holds four weekly doses) if you meet its body mass index (BMI) and health rules.²⁵ Anyone already getting a GLP-1 through their Part D plan is among the people it leaves out.²⁵ Zepbound's label warns never to share a KwikPen, even after changing the needle, because blood-borne infections can spread.⁵ Our UnitedHealthcare page sets out the Bridge's rules, and Medicare.gov has the program's own summary.
• You have type 2 diabetes. Mounjaro, Lilly's other tirzepatide brand, is approved to improve blood sugar, along with diet and exercise, in adults and children 10 and older with type 2 diabetes, and to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes who are at high risk for them; weight loss is not among its approved uses.⁶ Ask whoever treats your diabetes.
• You have Medicaid, TRICARE or VA care. See our pages on Medicaid coverage and TRICARE and VA coverage.

If your doctor agrees: pharmacy, consent, follow-up and cost

Choosing and checking the pharmacy

The prescription goes to a state-licensed compounding pharmacy, the 503A kind, and that pharmacy should hold a license from your state's board of pharmacy.^{9, 26} To check, open FDA's BeSafeRx page, pick your state and search its board of pharmacy's license database. If the pharmacy is missing from it, FDA's advice is to not use it.²⁶ Our provider guide's checks before you pay cover the rest, from sterile compounding to FDA's inspection and warning-letter records.

The consent conversation

The OMA's 2023 position says patients should at minimum be told the limits of compounded products, and its 2024 checklist asks for a signed consent document.^{19, 21} Both malpractice insurers tell prescribers to document the discussion, and MICA says it should include FDA's information about the risks of compounded drugs.^{18, 22} Put together with FDA's own statements, those documents point to a conversation that covers:

• that the medicine is compounded, has no FDA approval and was not reviewed by FDA for safety, effectiveness or quality;⁷
• the documented reason it suits you better than an approved drug;¹²
• which pharmacy makes it, and that no prescriber can guarantee exactly what a compounded product contains;¹⁸
• risks MedPro names, such as wrong doses drawn from multidose vials and contamination;²²
• the label warnings and warning signs in the screening section.

Doses and follow-up visits

Your dose, schedule and any increases come from your prescriber and the pharmacy label, not from this page. FDA tells prescribers to be vigilant when setting compounded tirzepatide doses and how fast to raise them. It has adverse event reports that may be related to compounded doses beyond the approved label, such as larger single doses, more frequent doses or faster increases.⁷ With compounded semaglutide injections, it also has reports of adverse events, some needing hospital care, that may be related to dosing errors by patients measuring the wrong dose and, in some cases, clinicians miscalculating it.⁷

FDA also encourages patients to ask their prescriber or the pharmacy how to measure and give each dose.⁷ Before you start, ask how often you will be seen, how your other medicines will be adjusted and whom to call about side effects. Our pen and vial guide compares the two forms.

What it costs, and what insurance does

Plan on paying cash unless your plan confirms coverage in writing. For example, UnitedHealthcare's commercial policy approves a compound only if every condition is met. Those include use for an FDA-approved indication, the drug's own prior authorization criteria and a specific need, such as an allergy to an inactive ingredient in the commercial product.²⁷ Medicare's GLP-1 Bridge covers only the brand-name drugs it lists.²⁵ Our UnitedHealthcare page walks through that insurer's policy.

What compounded tirzepatide costs, and what a prescriber's visit adds, varies by seller; our tirzepatide cost page compares offers and fees.

What your prescriber should screen for, and warning signs to act on

Compounded tirzepatide has no FDA label. In FDA's experience, many adverse events reported with compounded products match those known for the approved drugs.⁷ So a careful prescriber screens against the two approved tirzepatide labels, Zepbound's and Mounjaro's, which share a boxed warning and most other warnings.^{5, 6}

The list below is not every risk; read the Zepbound label and Medication Guide and the Mounjaro label for the full text. Talk through each item with your prescriber, with one exception: if a sign below calls for stopping the medicine and getting help right away, act first.

What your prescriber should ask before writing it

• MTC or MEN 2 (the boxed warning). In rat studies, tirzepatide caused thyroid C-cell tumors; it is not known whether it does so in people. Neither label allows it for anyone with a personal or family history of medullary thyroid carcinoma (MTC), a form of thyroid cancer, or for anyone with MEN 2 (multiple endocrine neoplasia syndrome type 2).^{5, 6}
• Allergies. Both labels also rule it out for anyone who has had a serious allergic reaction to tirzepatide or to anything else in the product.^{5, 6} A compounded product's other ingredients may differ, so ask the pharmacy for the full list.
• Stomach and pancreas. Both labels advise against it for people with severe gastroparesis, a condition in which the stomach empties very slowly, and the Medication Guide asks about past pancreas problems.^{5, 6}
• Diabetes medicines and eyes. Low blood sugar is more likely with insulin or a sulfonylurea, and Zepbound's label reports it in adults without type 2 diabetes too. Anyone with a history of diabetic retinopathy needs monitoring for worsening.^{5, 6}
• Pregnancy and breastfeeding. Both labels warn that tirzepatide may harm an unborn baby; Mounjaro's label bases that warning on animal studies.^{5, 6} If you take compounded tirzepatide for weight loss and think you may be pregnant, tell your prescriber at once. Zepbound's label, the nearer match for that use, says to stop using it once a pregnancy is recognized.⁵ Mounjaro's label, for type 2 diabetes, says to use it in pregnancy only if the possible benefit justifies the possible risk, so on Mounjaro, call your prescriber rather than stopping by yourself.⁶ Both Medication Guides say it may pass into breast milk, so raise breastfeeding with your prescriber too.^{5, 6}
• Birth-control pills. Both labels say to change to a non-oral method, or use a barrier method as well, for the first 4 weeks and for 4 weeks after every dose increase.^{5, 6}
• Other medicines. Tirzepatide slows stomach emptying, so pills such as warfarin may need closer monitoring. Zepbound's label advises against combining it with another tirzepatide product or any GLP-1 receptor agonist, which would include compounded semaglutide.⁵
• Planned procedures. There are rare reports of food or liquid getting into the lungs of people on GLP-1 drugs during general anesthesia or deep sedation. Make sure every clinician planning a procedure for you knows you take it.⁵
• Whether you fit an approved use. With a reduced-calorie diet and more physical activity, Zepbound is approved for adults with obesity and for adults with overweight plus at least one weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity.⁵ The trial behind its weight approval defined obesity as a BMI of 30 or higher, and overweight as a BMI from 27 up to 30 with at least one condition such as high blood pressure.⁵ Other uses of tirzepatide, beyond Zepbound's uses and Mounjaro's uses in type 2 diabetes, are off-label, and compounded tirzepatide has no approval at all.⁷ If that may be you, talk it through with your own doctor, who can say whether an approved drug fits, before you turn to any online seller of compounded tirzepatide, such as PlexusDx. See our page for people who are not obese or overweight.

Warning signs after you start

Stop the medicine and get help right away for:

• trouble breathing or swallowing, a swollen face, lips, tongue or throat, fainting or feeling dizzy, a very rapid heartbeat, or a severe rash or itching: possible serious allergic reaction, so get medical help;⁵
• severe pain in your stomach area that will not go away, with or without nausea or vomiting, sometimes felt through to your back: possible pancreatitis, which has been fatal in some cases, so call your prescriber.⁵

Report these to your prescriber:

• clay-colored stools, yellowing of the skin or eyes, fever, or pain in the upper stomach: possible gallbladder problems, which happen more often with these drugs, so call right away;⁵
• nausea, vomiting or diarrhea that won't stop: call right away, and keep drinking fluids, because losing fluids can lead to kidney injury, in some cases needing dialysis;⁵
• stomach problems that are severe or do not go away;⁵
• signs of low blood sugar, such as sweating, shakiness, confusion, dizziness, hunger or a fast heartbeat;⁵
• any change in vision, if you have type 2 diabetes;⁵
• hoarseness, a lump or swelling in the neck, shortness of breath or trouble swallowing, which may be symptoms of thyroid cancer.⁵

If you take too much, call your prescriber or Poison Help at 1-800-222-1222, or go to the nearest emergency room right away.⁵

Extra cautions with a compounded product

FDA's tally of adverse event reports associated with compounded tirzepatide stood at more than 730 on May 31, 2026. FDA can't always tell whether the drug caused a reported problem. The true count is probably higher, since federal law requires only outsourcing facilities, not other state-licensed pharmacies, to send these reports to FDA.⁷

Throw out a multiple-dose vial 28 days after you first use it, even with medicine still inside, FDA advises. It also says to use a new sterile needle and syringe each time you inject and not to use a shipment that arrives warm.⁷ Our provider guide's arrival checklist covers the rest of what to look for when a box comes. Tell your prescriber about side effects, and report them to FDA through MedWatch, its safety reporting program.^{7, 28}

Getting it somewhere else? Keep your own doctor in the loop

The authors of a primary care records study say many patients may get compounded GLP-1s outside coordinated care. In records for 153,044 people using semaglutide or tirzepatide from 2021 to 2024, compounded use was documented for 8.2%, below the roughly 23% that surveys report getting these drugs from compounders.²⁹

Your doctor can still help after declining to prescribe it. Two authors at Yale School of Medicine, one a primary care physician, write that many clinicians do not recommend compounded GLP-1s. When a patient starts one anyway, they write, the clinician can see the patient regularly, watch for side effects and adjust other medicines.³⁰

Tell your doctor which product you take, who prescribed it and which pharmacy made it, especially if you use insulin, a sulfonylurea, warfarin or birth-control pills, or have a procedure coming up. If you later want to move to the brand, see our page on moving from compounded tirzepatide to Zepbound.

PlexusDx's prescribers and the written-reason rule

PlexusDx publishes this page and has a financial interest in compounded GLP-1 treatment, so the questions this page tells you to put to any prescriber apply to it too. Its answers below are as of October 19, 2026.

• The written reason. Lone Star Virtual Health's chart templates, it says, call for the prescribing physician to set down, for each patient, why the compounded formulation suits that person better than an FDA-approved drug they could use instead, such as Zepbound, and to tell the patient that reason and that compounded medicines lack FDA approval. It has no standard reason, and one resting on added B12, B6 or glycine must fit the patient's clinical needs. Because FDA's guidance expects the pharmacy to find the reason on the prescription itself, ask whether yours carries it there as well as in your chart (see what the prescription has to show).
• Who prescribes. PlexusDx handles the technology, payments, support and care coordination; it does not practice medicine. The prescribers are clinicians from Lone Star Virtual Health, PlexusDx's provider team in all 50 states, and they decide whether you get a prescription, at what dose, and whether treatment continues or stops. If you enroll, one of them, not your own doctor, makes that call, so keep your own doctor informed as described above. You learn which Lone Star provider is treating you after you complete the intake form, after entering card details but before any charge. Lone Star has only licensed physicians prescribe, so that provider will not be a nurse practitioner or physician assistant. PlexusDx and its telehealth platform, Bask Health, vet Lone Star and its physicians, but PlexusDx doesn't publish dates for its prescriber license checks, so check your provider's license once you know the name (our provider guide shows how).
• Who can enroll. PlexusDx serves adults 18 and older only. A Lone Star clinician reviews your health information before anything is prescribed, and approval is never guaranteed. Lone Star says its physicians make the final decision, applying the same rules to tirzepatide, semaglutide and Microdose GLP-1: BMI 25 or higher for new patients, and 22 or higher for anyone who took a GLP-1 drug in the two months before enrolling. Zepbound's approval for weight loss starts at BMI 30, or 27 if you have a weight-related condition, so starting someone below that would be off-label. Measured against this page's screening list, the intake asks every patient about pancreatitis, gastroparesis, thyroid cancer and MEN 2 in relatives, insulin and sulfonylureas, and current or recent semaglutide or tirzepatide, and asks women about pregnancy and breastfeeding; it does not ask about diabetic retinopathy, a coming procedure with sedation, or a B12 or glycine allergy, so raise those with your clinician. Lone Star requires live visits before a first prescription in 12 jurisdictions (our provider guide lists them). If you don't fit Zepbound's approved uses, start with your own doctor, as described above.
• Cost and billing. Under PlexusDx's Terms of Service, the programs are self-pay and no health insurance is billed. If a Lone Star clinician does not approve treatment, you owe $0. Plans of 3, 6 or 12 months are charged in full when the prescription is sent to the pharmacy, and every plan renews automatically unless you cancel or pause it. PlexusDx's Refund & Cancellation Policy sets out cancellations and refunds, and our telehealth programs page compares billing terms.
• The pharmacy. The medicine comes from a licensed partner pharmacy, not from PlexusDx, and every pharmacy PlexusDx works with is a state-licensed 503A compounding pharmacy; between them they cover all 50 states. If a clinician finds a prescription appropriate, you may name the pharmacy you'd like to fill it; PlexusDx's Terms make that depend on availability and legal requirements, and without a request a pharmacy is assigned. Your patient portal shows an assigned pharmacy's name after you are approved for treatment, and the card is charged when the prescription is sent to the pharmacy, so if you want to check the pharmacy first, request one you have already looked up. Once you know the name, you can look up the pharmacy's license as described above.
• What is prescribed. The tirzepatide that PlexusDx's partner pharmacies dispense is compounded, and like all compounded tirzepatide it has no FDA approval.⁷ PlexusDx's Terms of Service say the formulation and any added ingredients may differ by pharmacy and by fill. Microdose GLP-1, PlexusDx's lower-dose plan, can be made with compounded tirzepatide or compounded semaglutide, and it is off-label. For a tirzepatide injection, Zepbound's label uses 2.5 mg a week only as a starting dose and sets 5, 10 or 15 mg a week for ongoing weight loss.⁵ Taking less than that over time is outside its approved use.⁵ This page's screening list is for tirzepatide. If you are offered semaglutide, ask your prescriber to go through that drug's own label, Ozempic's or Wegovy's, because it has its own warnings.^{31, 32} Through PlexusDx, compounded tirzepatide is prescribed either as a weekly shot or as a daily orally disintegrating tablet (ODT). The injection always includes a second ingredient, vitamin B12 or glycine: California residents choose between them in the intake; elsewhere the dispensing pharmacy decides, and checkout gives no sign of which. Lone Star says any reason resting on the add-in must fit the patient's clinical needs. The tablets' inactive and added ingredients are not listed publicly. No tirzepatide tablet is FDA-approved. Microdose tirzepatide injections, made with B12, range from 1 mg to 4 mg a week, with the prescriber setting each dose. Report any allergy in the intake, where it goes to the physician for a decision; vitamin B12 and glycine aren't on its allergy checklist, so list them yourself. FDA's point about added ingredients, under what the prescription has to show, applies to these products as to anyone's.
• Consent. Yes, in two parts. Before checkout, right after you give your height and weight, a consent screen says that compounded medicines are not FDA-approved and have not been evaluated by FDA for safety, effectiveness or quality, gives the BMI levels used for FDA-approved weight-loss drugs, and says your physician will explain any off-label use before treatment. After you enter card details at checkout, but before any charge, a GLP-1 consent lists common side effects such as nausea, vomiting, diarrhea and constipation and serious ones including pancreatitis, low blood sugar with other diabetes medicines, gallbladder disease, kidney problems and allergic reactions, notes thyroid tumors seen in animal studies and calls for follow-up visits; a final consent repeats the statement about FDA. The screens do not name your pharmacy or the reason recorded for you, both of which the consent conversation above covers, and they summarize rather than reproduce the label warnings in the screening section.
• Follow-up. The plan price includes clinically required live consultations and ongoing oversight from your Lone Star clinician. Lone Star generally may prescribe up to six months of treatment at a time when clinically appropriate, and continuing past that takes a renewed clinical review. If you think you are having a medical emergency, call 911 or seek immediate in-person emergency care, as PlexusDx's Safety Information page also tells patients. For the signs listed above, follow the instruction given with each one.
• Brand-name drugs. Lone Star Virtual Health's clinicians decide whether to prescribe. PlexusDx does not sell or ship brand-name medications. If you would prefer a brand-name, FDA-approved medication, your provider may write a prescription you can fill at the pharmacy of your choice.

Sources

1. 21 U.S. Code § 353 - Exemptions and consideration for certain drugs, devices, and biological products, Legal Information Institute, Cornell Law School, accessed October 3, 2026.
2. Getting started with licensure, U.S. Department of Health and Human Services (Telehealth.HHS.gov), accessed October 3, 2026.
3. State Practice Environment, American Association of Nurse Practitioners, accessed October 3, 2026.
4. What is a PA?, American Academy of Physician Associates, accessed October 3, 2026.
5. ZEPBOUND (tirzepatide) injection: prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
6. MOUNJARO (tirzepatide) injection: prescribing information, Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 4, 2026.
7. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration, accessed October 3, 2026.
8. Compounding when Drugs are on FDA's Drug Shortages List, U.S. Food and Drug Administration, accessed October 3, 2026.
9. 21 U.S. Code § 353a - Pharmacy compounding, Legal Information Institute, Cornell Law School, accessed October 3, 2026.
10. Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry (December 2016), U.S. Food and Drug Administration, accessed October 4, 2026.
11. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S. Food and Drug Administration, accessed October 4, 2026.
12. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry (January 2018), U.S. Food and Drug Administration, accessed October 4, 2026.
13. Assessing Awareness, Confidence and Utilization of Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists Among Healthcare Clinicians and Pharmacists: A Comprehensive Survey Study, Umbreit A, et al., Journal of Primary Care & Community Health, 2026, accessed October 3, 2026.
14. Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, State of Ohio Board of Pharmacy, accessed October 3, 2026.
15. Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy, Courtney LA, et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2025, accessed October 3, 2026.
16. The American Diabetes Association Announces Statement on Compounded Incretin Products (December 2, 2024), American Diabetes Association, accessed October 3, 2026.
17. Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association, Neumiller JJ, et al., Diabetes Care, 2025, accessed October 3, 2026.
18. Evaluating Risk When Prescribing Compounded Semaglutide (August 6, 2024), MICA (Mutual Insurance Company of Arizona), accessed October 3, 2026.
19. Frequently asked questions to the 2023 Obesity Medicine Association position statement on compounded peptides: A call for action, Bays HE, et al., Obesity Pillars, 2024, accessed October 3, 2026.
20. Leading Obesity Expert Organizations Release Statement to Patients on Compounded GLP-1 Alternatives (January 8, 2024), Obesity Medicine Association, with the Obesity Action Coalition and The Obesity Society, accessed October 3, 2026.
21. Obesity Medicine Association Issues a Position Statement on Compounded Peptides (March 30, 2023), Obesity Medicine Association, accessed October 3, 2026.
22. Risk Management Strategies for Prescribing Weight-Loss Medications, MedPro Group, accessed October 3, 2026.
23. Zepbound (tirzepatide): Full Terms and Conditions, Eli Lilly and Company, accessed October 3, 2026.
24. Zepbound (tirzepatide) | LillyDirect, Eli Lilly and Company, accessed October 4, 2026.
25. Weight loss drugs, Medicare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
26. Locate a State-Licensed Online Pharmacy (BeSafeRx), U.S. Food and Drug Administration, accessed October 3, 2026.
27. Compounds and Bulk Powders - Prior Authorization/Notification - UnitedHealthcare Commercial Plans (effective July 1, 2026), UnitedHealthcare, accessed October 3, 2026.
28. MedWatch: The FDA Safety Information and Adverse Event Reporting Program, U.S. Food and Drug Administration, accessed October 3, 2026.
29. Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset, Hendrix N, et al., Pharmacoepidemiology and Drug Safety, 2025, accessed October 3, 2026.
30. Compounded GLP-1 Receptor Agonists: Opportunity for Compassionate Conversation, Chetty AK, Chen AS, Journal of General Internal Medicine, 2026 (published online July 22, 2025), accessed October 3, 2026.
31. OZEMPIC (semaglutide) injection: prescribing information and Medication Guide (revised 5/2026), Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 4, 2026.
32. WEGOVY (semaglutide) injection and tablets: prescribing information and Medication Guide (revised 6/2026), Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 4, 2026.

How we made this page

What a prescriber has to do before a pharmacy may compound tirzepatide is split across a federal statute, two FDA guidance documents (from 2016 and 2018) and FDA's April 2026 update. AI tools read those together on October 3, 2026, along with the federal prescription law, Ohio's GLP-1 guidance as one state's example, statements from diabetes, obesity and pharmacy groups, a 2026 survey of clinicians and pharmacists, a primary care records study, two malpractice insurers' advice, the Zepbound and Mounjaro labels and the other sources listed above. The tools set out what each document asks of a prescriber, a pharmacy and a patient, and drafted the page from that comparison.

AI reviewers read an earlier draft against FDA's documents, the Zepbound and Mounjaro labels and the other main sources listed above, and the page was corrected where they found a mismatch. An AI editor then compared every passage quoted from FDA's guidance and April 2026 update with the document itself and re-read FDA's three sample prescription notes there on October 4, 2026. For this page we interviewed no doctors, pharmacists or insurers, and the only sample prescription wording on it is FDA's own.

The older PlexusDx post at this address described compounding in terms FDA's rules do not support, promoted a genetic test and quoted prices; none of its text or claims was kept. What the page says about PlexusDx comes from PlexusDx's Terms of Service, its published policies and Jay Hastings's confirmations as of October 19, 2026, so it carries no source number.

Jay Hastings reviewed and approved this version on October 19, 2026. Dr. Asad K. Niazi, MD, MPH, reviewed the medical content on October 17, 2026. He is co-founder and CEO of Lone Star Virtual Health, the company that provides PlexusDx's prescribing clinicians, so he has a business relationship with PlexusDx. PlexusDx sells compounded GLP-1 treatment, so we have a financial interest in this topic. See our editorial policy.

Correction, October 28, 2026: PlexusDx's Microdose tirzepatide plan ranges from 1 mg to 4 mg a week, not 0.5 mg to 1.5 mg as this page first said, and the card is charged when the prescription is sent to the pharmacy, not at approval. Jay Hastings confirmed both points for PlexusDx on October 28, 2026.